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Abstract
Background: Tissue-engineered bone may be developed by seeding the cells capable of both
osteogenesis and vascularization on biocompatible composite scaffolds. The current study
investigated the performance of mice bone marrow-derived osteogenic cells and endothelial cells
as seeded on hydroxyapatite (HA) and poly-ε-caprolactone (PCL) composite scaffolds.
Methods: Mononuclear cells were induced to osteoblasts and endothelial cells respectively, which
were defined by the expression of osteocalcin, alkaline phosphatase (ALP), and deposits of calciumcontaining crystal for osteoblasts, or by the expression of vascular endothelial growth factor
receptor-2 (VEGFR-2) and von Willebrand factor (vWF), and the formation of a capillary network
in Matrigel™ for endothelial cells. Both types of cell were seeded respectively on PCL-HA scaffolds
at HA to PCL weight ratio of 1:1, 1:4, or 0:1 and were evaluated using scanning electron
microscopy, ALP activity (of osteoblasts) and nitric oxide production (of endothelial cells) plus the
assessment of cell viability.
Results: The results indicated that HA led to a positive stimulation of osteoblasts viability and ALP
activity, while HA showed less influence on endothelial cells viability. An elevated nitric oxide
production of endothelial cells was observed in HA-containing group.
Conclusion: Supplement of HA into PCL improved biocompatible for bone marrow-derived
osteoblasts and endothelial cells. The PCL-HA composite integrating with two types of cells may
provide a useful system for tissue-engineered bone grafts with vascularization.

Background
One approach to tissue engineering consists of seeding
appropriate cells on a biodegradable scaffold, stimulating
cell growth and differentiation in vitro, and then implanting the engineered complex in vivo to achieve functional
tissue [1,2]. However seeding a single cell type into a biomaterial scaffold to replace an injured tissue that consists
of multiple cell types is usually inapplicable. An alterna-

tive strategy is the generation of a composite graft, which
contains not only the tissue specific cell types, but also
other supportive cells, such as endothelial cells (ECs) to
promote vascularization of the grafts.
ECs may be incorporated into bioengineered tissue[3,4]to
promote the tissue revascularization, and transportation
of oxygen and nutrients. Unfortunately, differentiated ECs
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isolated from most tissues including aortas, dermal capillaries and umbilical veins have inadequate proliferating
capacities and are less responsive to angiogenic survival
factors or anti-angiogenic signals [5,6]. In contrast, bone
marrow-derived endothelial progenitor cells (EPCs) possess high potential for neovascularization and reendothelialization [7]. EPCs isolated from bone marrow or
peripheral blood have been observed to undergo more
than 1000 division cycles [8], indicating that even the
comparatively low numbers of adult EPCs may provide
sufficient seeding cells for tissue engineering applications.
Bone marrow stromal cells (MSCs) are multipotent stem
cells originating from the bone marrow stroma, and represent a particularly promising cell source for bone tissue
engineering. They can be easily harvested, expanded in
vitro and induced to differentiate to bone-forming cells
[9]. We have therefore selected MSCs as the source of osteogenic precursors for tissue engineered bone in this
project. Polycaprolactone (PCL), an FDA-approved polyester commonly as drug delivery devices used in clinical
practice, has been shown to be non-toxic to cells [10,11],
possessing many of the desirable properties such as
degradability and plasticity. Hydroxyapatite (HA) is the
inorganic part of the naturally occurring bone, and is
known to be both biocompatible and osteoconductive. It
suggests that the addition of HA to PCL will improve the
biocompatibility and osteoconductivity of the polymer
[12-14]. However, the precise dose-response relationship
of HA in PCL on viability and osteogenic functions of
bone marrow-derived osteoblasts remains to be elucidated. Although ECs-initiating vascularization in the engineered bone is critical [15], the survival and bioactivity of
EPCs-originated ECs in biomaterials of bone graft is frequently neglected. Therefore, the objective of this study
was to evaluate the biocompatibility of the HA-PCL biomaterials to both bone marrow-derived osteogenic and
endothelial cells.

Methods
Cell Culture and Induction
Bone marrow cells were obtained from male BALB/c mice
(6–8 weeks of age). Low-density bone marrow mononuclear cells (MNCs) were isolated by density centrifugation
over Histopaque®-1083 (Sigma-Aldrich, US). Cells were
then cultured in flask at 37°C and 5% CO2 atmosphere
for differentiation of osteoblasts and endothelial cells,
respectively. For osteogenic cell induction, cells were cultured in complete media [16,17] consisting of DMEM
supplemented with 10% fetal bovine serum (FBS) (Invitrogen, US), 10 mM β-glycerol phosphate (Sigma-Aldrich,
US), 10-4 M L-ascorbic acid (Sigma-Aldrich, US), and 10
nM dexamethasone (Sigma-Aldrich, US), 2 mM
glutamine (Invitrogen, US), 100 U/ml penicillin (Invitrogen, US), 100 μg/ml streptomycin (Invitrogen, US). To
promote the endothelial phenotype of EPCs, the mono-
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nuclear cells were plated onto flasks coated with fibronectin (Sigma-Aldrich, US) and cultured in endothelial cell
basal medium-2 (Cambrex, US) supplemented with
EGM-2 MV SingleQuot® kit containing 5% FBS, human
epidermal growth factor (hEGF), human vascular
endothelial growth factor (VEGF), human insulin-like
growth factor-1 (IGF-1), hydrocortisone, penicillin (Invitrogen, US), and streptomycin (Invitrogen, US). After 4
days of culture, non-adherent cells were discarded by
washing with PBS. When 60% confluence was achieved,
cells were subcultured.
Cell Characterization
Immunocytofluorescence studies were performed to
detect the induced endothelial phenotypes. The induced
ECs were fixed in 4% paraformaldehyde, permeated with
0.01% Triton X-100 in PBS, and incubated in 1% block
serum for 1 h at 37°C. The cells were then incubated for 1
hour with monoclonal antibody against either mouse
VEGFR-2 or mouse vWF (Santa Cruz, US). Bound antibodies were detected by incubation with fluorescein-5isothiocyanate (FITC)-conjugated (Jackson ImmunoResearch, US) (for VEGFR-2) or Alexa Fluor 488-conjugated
(Molecular Probes, US) (for vWF) secondary antibody.
The cells were examined in fluorescence microscope. 300
μl of Matrigel™ (BD Biosciences, US) mixed with 4 × 104
EPCs-derived ECs at 4°C was dispensed into a 24-well
plate and incubated at 37°C until solid. Photographs of
capillary-like formation were taken at 7 days of culture in
normal condition.

Similar fixation, permeabilization, and blocking processes were performed on bone marrow-derived osteoblasts, followed by the incubation with anti-osteocalcin
(Santa Cruz) for 1 hour, and visualization was achieved
using avidin-peroxidase complex (ABC kit, Santa Cruz
Biotechnology, US). Cells were counterstained with Gill's
hematoxylin solution. Calcium deposit produced by osteoblasts was demonstrated using von Kossa staining. After
fixation in 4% paraformaldehyde, the cells were incubated with 1% silver nitrate solution (Sigma-Aldrich, US)
under ultraviolet light for 20 minutes, and unreacted silver was removed by 5% sodium thiosulfate (SigmaAldrich, US). The alkaline phosphatase (ALP) activity of
osteoblasts was assayed using an ALP kit (Sigma-Aldrich,
US). The induced osteoblasts on slides were fixed in citrate-acetone-formaldehyde solution at room temperature
for 1 minute. Following incubation in alkaline-dye mixture for 15 minutes and rinsing in distilled water, the
slides were counterstained with hematoxylin solution.
Preparation of HA-PCL Scaffolds
PCL-HA scaffolds were prepared using a particulate leaching technique as described previously [18]. The HA-PCL
composite at 2 different component ratios were prepared
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respectively, with HA (Sigma-Aldrich, US) to PCL
(Aldrich, US) at 1:1 (Group A) or 1:4 (Group B) wt/wt.
PCL scaffolds without HA were used as a control (Group
C). In each group, NaCl particles (particle size 212–355
μm) were used to generate a controlled level of porosity in
the matrix with weight ratio to PCL at 16:1 (Group A), 8:1
(Group B) and 4:1 (Group C). PCL (Mn 80000) was dissolved in tetrahydrofuran (Sigma-Aldrich, US) at 10% wt/
vol for 12 hours. HA powder (≤ 40 μm particle size) and
NaCl particles were mixed to homogeneity in the PCL
solution, which was sonicated for 60 seconds until viscous slurry developed. Mixtures were poured into glass
dishes to a thickness of 4 mm, and dried at 37°C. After
evaporation of the solvent, 1.5 × 1.5 cm squares were cut
out and washed in excessive distilled water to leach out
the NaCl. All materials were then sterilized in 70% ethanol and dried before biological evaluation. Samples of the
PCL-HA scaffolds were gold sputter coated and their morphology was observed using SEM (Hitachi S-2400, Japan)
at 15 kV. Energy Dispersive X-ray (EDX) analysis was also
conducted to confirm the existence of HA particles on the
composite scaffolds. The atomic percentages of calcium
and phosphorus were calculated.
Cells Culture on Scaffolds
Induced osteoblasts or endothelial cells in 50 μl suspensions (3.5 × 106 cells/ml) were respectively loaded onto
each scaffold in 6-well plates. The scaffolds were left
undisturbed in a 37°C incubator for 3 hours to allow cells
to attach to the scaffold, after which the cells-materials
complex were kept in culture using the original osteogenic
or endothelial media. At day 7 the samples were harvested
for and biochemical evaluation.

For morphological examination, cells-materials complex
were fixed with 1.5% glutaraldehyde (Fisher Scientific,
US) for 30 min at 4°C. The samples were exposed to 2%
osmium tetroxide (Sigma-Aldrich, US) for 30 min. Following rinse in distilled water, they were dehydrated
through a graded series of ethanol (50, 70, 90, and 100%)
for 2–5 min. The dehydration was completed in hexamethyl disilazane (Fluka, Germany) for 10 minutes. After airdrying and sputter coating with gold, the cells morphology on the PCL-HA scaffolds was evaluated using SEM at
10 kV.
Assessment of Cell Viabilities and Functions on Scaffolds
For biochemistry assay, each type of cells was seeded on
30 scaffolds per group. Cell viability was evaluated by analyzing the mitochondrial activities of the cells. The Alamar
Blue assay (BioSource, US) was used to determine the
mitochondrial activity after 7 days of cell culture. The
cells-materials complexes were washed in PhosphateBuffered Saline (PBS) in 6-well plate. 3 ml of new conditioned media supplemented with 200 μl of Alamar blue
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was added to each well. Incubation was continued at
37°C, 5% CO2, for 3 hours. The culture medium was then
transferred to a 96-well plate and read on a spectrofluorometer (excitation wavelength 530 nm, emission wavelength 590 nm). The Alamar blue absorbance/mg of DNA
values was calculated for each sample.
Cell amount were determined by a fluorometric quantification of DNA in the cells-materials complexes. After the
Alamar Blue assay, the cell-scaffolds were rinsed with PBS,
followed by 4 times of freezing (-80°C) and thawing
(37°C) cycles for 15 minutes each. The scaffolds were
then homogenized in 1.4 ml of cold 10 mM EDTA solution (Sigma-Aldrich, US). The pH of the samples was
adjusted to 7.0 by adding 1 M KH2PO4 prior to the addition of 1.5 ml of the 200 ng/ml Hoechst 33258 fluorescent dye (Sigma-Aldrich, US). 100 μl of supernatant
sample were read with an excitation set at 350 nm and an
emission at 455 nm on a spectrofluorometer. The DNA
concentration in the samples was determined against a
DNA standard curve that was plotted according to a series
of 100 μl of calf thymus DNA (Sigma, US) in a range of
concentrations from 0.15265 to 20 μg/ml. The DNA values were used to normalize the cell viability and other cell
function parameters.
Production of ALP by osteogenic cells was measured using
a spectrophotometer. After the previous freeze-thaw cycle
and DNA assay, 50 μl of the sample was transferred to a
fresh 96-well plate and 50 μl of p-nitrophenyl phosphate
solution (Sigma, US) was added to each sample. Following incubation for 5 min at 37°C, the production of pnitrophenol in the presence of ALP was measured by
monitoring light absorbance at 405 nm. The measurement of the ALP assay was normalized against the amount
of total DNA in each sample.
The nitric oxide generated by endothelial cells on scaffolds was assessed using the Nitric Oxide Colorimetric
Assay kit (Calbiochem, Germany) in accordance with the
manufacturer's instructions. The presence of nitric oxide
in the culture media of endothelial cells-materials complex was determined by detecting the colored product
spectrophotometrically. The absorbance was read at 540
nm. The nitric oxide concentrations for samples were calculated according to the standard curve. Cellular nitric
oxide amount was normalized by total DNA each sample.
Statistical Analysis
All experiments were replicated three times to ensure the
reproducibility, and all data was presented as the mean ±
standard deviation. Single factor analysis of variance
(ANOVA) with a post hoc LSD from SPSS™ (Student Version 10.0.5, Chicago, IL) was used to assess the statistical
significance among groups, which was defined as p < 0.05.
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Results
Cells Culture and Induction
Cell colonies were detected in the primary passage using
culture conditions with either osteogenic medium or
endothelial medium. These cells differentiated and proliferated, and gradually exhibited homogeneous and specific cell morphologies. The differentiated cells displayed
osteoblasts-like spindle morphology in osteogenic
medium (Figure 1A), while endothelial cells presented
typical cobblestone morphology (Figure 1B). These cells
retained stable morphologies for more than 5 passages.
We choose the 2nd passage osteoblasts and endothelial
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cells for subsequent cell characterization and the investigation of biocompatibility.
Cell Characterization
The capacity of the induced osteoblasts to express osteocalcin was examined by immunocytochemistry (IHC)
(Figure 2A). The expression of osteocalcin was detected in
over 95% osteogenic-wise induced cells. These cells were
also identified by positive staining for ALP (Figure 2B),
which indicated that the induced cells possessed distinguishable osteoblastic phenotype. To demonstrate the
ability of cells to mineralize matrix, cells cultured on Petri
dishes were subjected to von Kossa stain to reveal calcium
deposition (Figure 2C) where the darkly stained mineralized nodule were visualized by silver nitrate, indicating
normal osteoblasts function in conditioned culture. Differentiation ability of ECs induced from bone marrow was
determined by the expression of endothelial markers,
VEGFR-2 and vWF, using immunocytofluorescence. The
95% endothelial-wise-induced cells expressed VEGFR-2
and vWF at 2nd passage of culture (Figure 3A, B), indicating the induced cells having normal endothelial phenotype. Matrigel™ culture was performed to monitor the
capability of capillary formation. Three-dimensional capillary-like networks from EPCs-derived endothelial cells
were clearly established at one-week incubation (Figure
3C).
Cells Culture on Scaffolds
PCL scaffolds incorporated with or without HA were fabricated with controlled porosity (70% ~ 75%) and pore
sizes. Interconnected pore morphologies were present in
all scaffolds, resulting in the high porosity of the scaffolds.
Different microtopographies of scaffolds were revealed by
scanning electron microscopy (SEM) (Figure 4). The
roughness of pore wall appeared dependent on the ratio
of HA to PCL. High HA concentration led to extensive protrusions of HA particles and rough surfaces (Figure 4C),
while an almost smooth pore wall was achieved in the
PCL scaffold without HA incorporation (Figure 4A). EDX
analysis indicated atomic ratio of calcium to phosphorus
(Ca: P = 1.58) on both low HA ratio (HA: PCL = 1:4) and
high HA ratio (HA: PCL = 1:1) composite scaffolds, which
is comparable to a natural hydroxyapatite (Figure 4D).

Figure 1 of osteoblasts and endothelial cells
Morphology
Morphology of osteoblasts and endothelial cells. During the 2nd passage, the mice bone marrow-derived mononuclear cells differentiated to osteoblasts exhibiting the
spindle morphology (Panel A), or differentiated to endothelial cells presenting the typical cobblestone morphology
(Panel B). Magnification 200×.

The specific cell morphology of either osteoblasts or
endothelial cells displayed rarely difference response to
various groups of PCL-HA scaffold. The continuous culture of osteoblasts on HA-containing scaffolds for 7 days
revealed that cells retained their spindle morphology (Figure 5A) similar to the osteoblasts grown on tissue culture
flasks. Extracellular matrix (collagen-like fibers) was
clearly present at intercellular regions, where cellular projections were evident (Figure 5B). For the cultures of PCLHA scaffolds with bone marrow-derived endothelial cells,
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Figure 2
Characterizations
of osteoblasts
Characterizations of osteoblasts. Over 95% of induced
osteoblasts expressed osteocalcin visualized by immunocytochemistry stains (Panel A, 200×). Alkaline phosphatase (ALP)
activity of osteoblasts was assayed using an ALP kit and visualized as the pink color (Panel B, 200×). In addition, von
Kossa staining was performed to reveal ossification nodules
in the culture dishes of induced cells, as an indicator of osteoblasts function (Panel C, 200×).
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Figure 3
Characterization
of endothelial cells
Characterization of endothelial cells. Panel (A) illustrated the VEGFR-2 expression on the induced ECs (200×).
Over 95% of cells lighted up in dark-field microscope for
cytoplasmic vWF following cultures in EC conditional
medium (Panel B, 200×). After one-week incubation in a
Matrigel™ basement membrane system, these cells proliferated and developed capillary-like 3-D structures (Panel C,
200×), suggesting functional endothelial phenotype.
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Figure 4
Microstructure
of scaffolds exhibited by SEM
Microstructure of scaffolds exhibited by SEM. The HA
were embedded in PCL, or exposed on the surface. Apparently the roughness of pore-wall surfaces increased with
increasing the HA ratio. Panel (A) (800×) was an example of
HA-free PCL scaffolds. Panel (B) (1000×) showed composite
with low HA ratio, HA: PCL (w/w) = 1:4; while Panel (C)
(500×) revealed a sample with high HA concentration, HA:
PCL (w/w) = 1:1. The protruded components were confirmed as the HA by EDX (Panel D). The peaks of calcium
and phosphorus were prominent and quantified the atomic
ratio (Ca: P = 1.58).

1:1) morphology
Cells
Figure
5
on the composite scaffolds (HA: PCL =
Cells morphology on the composite scaffolds (HA:
PCL = 1:1). Panel (A) showed osteoblasts proliferating on
PCL-HA scaffolds (400×). Panel (B) was an enlargement of
Panel (A) showing the details of the attached osteoblasts
with meshwork of extracellular matrix (arrows), and cellular
projection (1500×). Panels (C) and (D) revealed the growth
of endothelial cells on a PCL-HA scaffold. The Panel (C) pictured ECs proliferating and forming a cell sheet (600×), and
Panel (D) magnified attached ECs to detail their cobblestone
shape and cellular extensions (4000×).

the cells completely covered the surface of the scaffolds at
7 days (Figure 5C). The spreading and paving endothelial
cells remained as typically cobblestone like shapes with
high cell-to-cell contact (Figure 5D). Cellular extensions
on the cells surface were also detected.

(Figure 6C), the HA involvement into PCL did lead to
36% (at HA: PCL = 1:1) (p < 0.05) and 80% (at HA: PCL
= 1:4) (p < 0.01) increase of nitric oxide production compared to the HA-free scaffolds (Figure 6D). There was not
statistically significant difference on NO production
between low and high HA ratio groups (p = 0.292, Figure
6D).

The biochemical tests would provide quantitive comparison on compatibility of biomaterials across various
groups. Comparisons were made among cell-scaffold
complexes that varied only in HA ratio to PCL. Addition
of HA resulted in a positive stimulation of osteoblasts viability (Figure 6A). Compared to the HA-free PCL material,
osteoblasts viability was increased by 740% (p < 0.001) in
high HA ratio (HA: PCL = 1:1) group and by 570% (p <
0.001) in low HA ratio (HA: PCL = 1:4) group, revealed by
the Alamar Blue assay. Similarly, as a marker of osteoblast
differentiation, ALP activity was increased by 240% in the
high HA ratio group (p < 0.01) and by 150% in low HA
ratio group (p < 0.05), suggesting the promotion of osteoblasts function due to the osteoconductivity of HA (Figure 6B). There were no statistically significant difference
between the two HA-containing groups in terms of osteoblasts viabilities (p = 0.083) and ALP activities (p =
0.119). Although the addition of HA into PCL did not
show significant influence on endothelial cell viability

Discussion
Bone tissues are essentially composite materials consisting of various components tissues with different structural
arrangements and functions. Repairing bone defects using
tissue engineered grafts involves the interplay of several
variables, including scaffold materials with excellent biocompatibility, osteogenic cells capable of assembling the
complicated and functional bone tissue, and an appropriate vascular bed to support the metabolic needs of new
bone tissue. We have been developing a composite scaffold consisting of PCL and HA to enhance the biomechanical properties as the potential bone graft substitute [19].
Furthermore, following introducing MSCs-derived osteoblast (responsible for osteogenesis) and EPCs-derived
endothelial cells (accountable for vascularization), we
attempted in the current study to evaluate the biological
impacts of various component ratios in PCL-HA scaffolds
on the two types of cells.
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a study [15]. It demonstrated that these differentiated
bone marrow-derived endothelial cells and osteoblasts
had the potential to create a tissue-engineered bone graft
with microvascular network. Therefore, it is necessary to
evaluated biological effects PCL-HA scaffolds on these
cells seeded on it.

tion of6 composite scaffolds on the cells viability and funcEffects
Figure
Effects of composite scaffolds on the cells viability
and function. The induced osteoblasts and endothelial cells
were separately cultured with the 3 groups of scaffold (30
scaffolds per group for each type of cell) for 7 days before
testing. Panels (A) and (C) summarized the Alamar Blue assay
for osteoblast and endothelial cell viabilities. Panel (B) plotted
alkaline phosphatase activity of osteoblasts on various scaffolds. Panel (D) showed the NO production of endothelial
cells on various scaffolds.

Large numbers of MSCs-originated osteoblasts and EPCsoriginated endothelial cells could be obtained in dish culture in vitro, making them possible to construct transplantable tissues scaffolds. It has been shown that in vitro
stem/progenitor cells possess the capability of selfrenewal and differentiation into organ-specific cell types
[20]. Our results indicated that MSCs and EPCs could be
harvested from mice bone marrow and differentiate into
osteoblasts and endothelial cells respectively. Besides the
expression of specific molecular markers like osteocalcin,
VEGFR-2, and vWF, induced MSCs and EPCs functioned
normally, as indicated by both fine crystals of ossification
(comparable to natural bone mineral) and ALP activity in
osteoblasts, and capillary-like formation by endothelial
cells in Matrigel™. Due to the capacity of capillary formation, it was speculated that induced endothelial cells
might participate or mediate the neovascularization in tissue engineered bone in vivo, which had been elucidated in

PCL and HA have been shown non-toxic and non-mutagenic biomaterials [11,21-24]. In particular, the biocompatibility of HA due to its similarities to natural bone
mineral have led to HA widespread use in bone reconstructive surgery. Degradation and metabolism of PCL
was completed in vivo, and ε-hydroxycaproic acid and
water were the only metabolites [22,25]. Our study indicated that inclusion of HA into PCL significantly increased
the mitochondrial activity and expression of ALP by osteoblasts in a dose-dependent manner, which is in agreement with previous studies [12,26]. The SEM images
demonstrated that bone marrow-derived osteoblasts were
spread on the scaffold surfaces with exposed HA particles
and synthesized extracellular matrix. Nitric oxide (NO) is
a biologically active molecule in the maintenance of vascular homeostasis and predominately produced by
endothelial cells. We examined the levels of NO in cell
media and in cell-scaffold composite to confirm and
quantify the function of bone marrow-derived endothelial cells. Our data showed that the addition of HA elevated NO production in comparison with the HA-free
PCL scaffolds, suggesting that HA particles promoted
functions of the endothelial cells. Although Pezzatini [27]
reported excellent biocompatibility of HA nanocrystals
for endothelial cells, cell viability experiments of this
study resulted no difference among endothelial cell
groups. The different culture conditions and cell origins,
disparate HA dimensions, and biomaterials architectures
between our and Pezzatini's investigations may partially
explain the diverse outcomes.
In this study, adding of HA into PCL led to heterogeneous
surface properties. Variety of HA ratio to PCL generated
distinct exposure of HA particle and diverse topography,
which have been evidenced by SEM images. The exposed
HA particles were more predominated on the high HA
ratio scaffold than those on the lower ones, where the HA
free scaffold just exhibited smoother surface on the pore
walls. It appears that the rough surfaces due to HA embedding provided more anchorage for cell process and
spreading, adhesion and orientation. Therefore, osteoblasts and endothelial cells were inclined to attach to the
rougher surface and appeared better viability and strong
cellular phenotypes, which supplement the literature
reports that cell number and attachment force were
increased on textured polymer substrates [26,28,29]. Furthermore HA is a well known sorbent for molecules.
Involvement of HA particles on the PCL surface may
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change the surface charge, reduce the hydrophobicity of
PCL and promote the adsorption of proteins and other
molecules from surrounding environment [30,31]. In
hard tissues, proteins such as osteopontin, bone sialoprotein, and osteocalcin were able to recognize HA through
highly acidic domains, resulting in the attachment and
distribution of osteogenic cells on the surface of proteincoated HA, and subsequently improving cell proliferation
and differentiation, and promoting new bone formation
[32-35]. Additionally the calcium ions released from the
dissolution of HA were able to neutralize PCL acidic products, so the adverse response due to the PCL degradation
could be overcame [14,36,37].

Conclusion
In conclusion, our data indicated that supplement of HA
into PCL provided a compatible environment for osteoblasts and endothelial cells to replicate and function. The
HA surface exposure accounted for the positive cellular
responses. Optimal component ratio in PCL-HA scaffold
could be selected in term of bioactivities of osteoblasts
and endothelial cells. These outcomes would contribute
to the construction of vascularized engineered bone in
vitro and implantation in vivo.
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